David B Solit Selected Research

tyrosine receptor (receptor, tyrosine)

1/2022	Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts.
12/2019	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.
7/2013	ERK pathway inhibitors: how low should we go?
11/2008	Genetic predictors of MEK dependence in non-small cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David B Solit Research Topics

Disease

185	Neoplasms (Cancer) 04/2024 - 02/2002
26	Melanoma (Melanoma, Malignant) 01/2022 - 05/2007
25	Carcinoma (Carcinomatosis) 11/2023 - 11/2003
17	Urinary Bladder Neoplasms (Bladder Cancer) 04/2024 - 10/2012
15	Breast Neoplasms (Breast Cancer) 11/2021 - 02/2002
14	Neoplasm Metastasis (Metastasis) 01/2023 - 01/2008
13	Colorectal Neoplasms (Colorectal Cancer) 01/2024 - 09/2010
13	Lung Neoplasms (Lung Cancer) 11/2020 - 07/2006
12	Adenocarcinoma 01/2024 - 11/2003
10	Prostatic Neoplasms (Prostate Cancer) 03/2024 - 05/2002
9	Disease Progression 01/2021 - 10/2003
7	Adenocarcinoma of Lung 01/2021 - 08/2007
5	Carcinogenesis 01/2024 - 01/2004
5	Microsatellite Instability 11/2023 - 01/2018
5	Ovarian Neoplasms (Ovarian Cancer) 11/2022 - 01/2012
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2022 - 01/2008
4	Histiocytosis 12/2023 - 02/2016
3	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2024 - 10/2020
3	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2022 - 07/2014
3	Stomach Neoplasms (Stomach Cancer) 01/2020 - 11/2008
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 05/2024 - 10/2012
2	Diarrhea 01/2024 - 12/2014
2	Squamous Cell Carcinoma of Head and Neck 10/2023 - 02/2017
2	Hepatocellular Carcinoma (Hepatoma) 01/2023 - 04/2019
2	Triple Negative Breast Neoplasms 11/2022 - 11/2020
2	Inflammation (Inflammations) 10/2022 - 01/2021
2	Pancreatic Neoplasms (Pancreatic Cancer) 10/2021 - 10/2017
2	Non-Muscle Invasive Bladder Neoplasms 01/2021 - 12/2017

Drug/Important Bio-Agent (IBA)

31	Phosphotransferases (Kinase)IBA 12/2023 - 05/2003
31	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 01/2008
28	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2024 - 12/2007
27	Biomarkers (Surrogate Marker)IBA 10/2023 - 04/2007
18	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2002
17	tanespimycin (17AAG)IBA 04/2012 - 02/2002
12	Cell-Free Nucleic AcidsIBA 02/2024 - 01/2017
11	PlatinumIBA 01/2024 - 01/2017
11	Immune Checkpoint InhibitorsIBA 10/2023 - 01/2018
11	ErbB Receptors (EGF Receptor)IBA 01/2022 - 03/2005
10	Cisplatin (Platino)FDA LinkGeneric 04/2024 - 07/2014
10	Mitogen-Activated Protein KinasesIBA 10/2018 - 12/2007
8	Trastuzumab (Herceptin)FDA Link 01/2023 - 12/2007
8	VemurafenibIBA 07/2015 - 07/2010
7	neratinibIBA 01/2024 - 01/2017
7	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2019 - 11/2008
7	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 12/2015 - 12/2007
6	Tyrosine Kinase InhibitorsIBA 01/2024 - 07/2006
6	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 03/2009
5	Poly(ADP-ribose) Polymerase InhibitorsIBA 02/2024 - 01/2019
5	raf KinasesIBA 07/2015 - 12/2008
5	Paclitaxel (Taxol)FDA LinkGeneric 01/2009 - 05/2003
4	Circulating Tumor DNAIBA 01/2023 - 01/2020
4	pembrolizumabIBA 01/2023 - 04/2019
4	NVP-BKM120IBA 11/2022 - 01/2019
4	tyrosine receptor (receptor, tyrosine)IBA 01/2022 - 11/2008
4	Hormones (Hormone)IBA 01/2020 - 10/2003
4	Ado-Trastuzumab EmtansineIBA 01/2020 - 01/2018
4	Proto-Oncogene Proteins B-rafIBA 08/2014 - 08/2008
3	ChromatinIBA 12/2022 - 02/2015
3	capivasertibIBA 01/2022 - 07/2017
3	RNA (Ribonucleic Acid)IBA 01/2022 - 09/2016
3	B7-H1 AntigenIBA 01/2021 - 01/2018
3	ParaffinIBA 01/2020 - 08/2012
3	Formaldehyde (Formol)FDA Link 01/2020 - 08/2012
3	AlpelisibIBA 01/2020 - 02/2015
3	human ERBB2 proteinIBA 12/2019 - 12/2007
3	Docetaxel (Taxotere)FDA Link 01/2019 - 03/2007
3	Estrogen ReceptorsIBA 10/2018 - 07/2017
3	LigandsIBA 01/2018 - 10/2003
3	AZD 6244IBA 12/2015 - 03/2010
3	Heat-Shock Proteins (Heat-Shock Protein)IBA 12/2014 - 05/2003
3	Oncogene Proteins (Oncogene Protein)IBA 03/2013 - 01/2006
3	MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA 08/2012 - 12/2007
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 09/2010 - 05/2003
3	Cyclin D1IBA 09/2010 - 11/2008
2	Gemcitabine FDA Link 04/2024 - 01/2018
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 02/2024 - 01/2023
2	Drug CombinationsIBA 01/2024 - 08/2015
2	dabrafenibIBA 01/2024 - 01/2012
2	trametinibIBA 01/2024 - 01/2018
2	regorafenibIBA 10/2023 - 01/2020
2	NivolumabIBA 10/2023 - 10/2018
2	Transcription Factors (Transcription Factor)IBA 11/2022 - 01/2008
2	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2022 - 01/2012
2	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA 05/2021 - 12/2020
2	Cyclin-Dependent Kinase Inhibitor p16IBA 01/2021 - 02/2015
2	Protein Isoforms (Isoforms)IBA 01/2021 - 01/2019
2	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 01/2008
2	CateninsIBA 01/2021 - 09/2011
2	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 01/2019
2	Cytotoxins (Cytolysins)IBA 01/2020 - 08/2013
2	Immunoconjugates (Immunoconjugate)IBA 01/2020 - 01/2018

Therapy/Procedure

93	Therapeutics 05/2024 - 01/2006
32	Drug Therapy (Chemotherapy) 04/2024 - 01/2008
12	Immunotherapy 11/2023 - 12/2017
11	Neoadjuvant Therapy 04/2024 - 01/2018
10	Castration 03/2024 - 05/2002
6	Cystectomy 04/2024 - 10/2014
3	Precision Medicine 10/2020 - 12/2015
2	Duration of Therapy 01/2023 - 01/2017
2	Aftercare (After-Treatment) 01/2021 - 12/2014